Fosamprenavir SR Oral Formulation

About N-Zyme Biotec

N-Zyme Biotec is pioneering a novel therapeutic approach for laryngopharyngeal reflux (LPR), a prevalent condition with no approved effective drug therapy. The company's core strategy involves the drug repurposing of fosamprenavir, a known HIV protease inhibitor, to inhibit pepsin—the key enzyme believed to cause tissue damage in LPR. With a Phase III clinical trial approved by the FDA and a strengthening intellectual property portfolio, N-Zyme is advancing a dual-formulation strategy (oral and inhaled) to address a significant unmet medical need affecting an estimated 10-30% of the U.S. population.

Therapeutic Areas